CA2980109A1 - Heterocyclic compounds and their use in preventing or treating bacterial infections - Google Patents

Heterocyclic compounds and their use in preventing or treating bacterial infections Download PDF

Info

Publication number
CA2980109A1
CA2980109A1 CA2980109A CA2980109A CA2980109A1 CA 2980109 A1 CA2980109 A1 CA 2980109A1 CA 2980109 A CA2980109 A CA 2980109A CA 2980109 A CA2980109 A CA 2980109A CA 2980109 A1 CA2980109 A1 CA 2980109A1
Authority
CA
Canada
Prior art keywords
nhq3
cndot
compound
nhq1
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2980109A
Other languages
English (en)
French (fr)
Inventor
Julie BRIAS
Audrey Caravano
Sophie Chasset
Francis Chevreuil
Fabien Faivre
Benoit Ledoussal
Frederic Le Strat
Sebastien Richard
Christophe Simon
Sophie VOMSCHEID
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mutabilis SA
Original Assignee
Mutabilis SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP15305479.6A external-priority patent/EP3075734A1/en
Application filed by Mutabilis SA filed Critical Mutabilis SA
Publication of CA2980109A1 publication Critical patent/CA2980109A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2980109A 2015-03-31 2016-03-30 Heterocyclic compounds and their use in preventing or treating bacterial infections Abandoned CA2980109A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP15305479.6A EP3075734A1 (en) 2015-03-31 2015-03-31 Heterocyclic compounds and their use in preventing or treating bacterial infections
EP15305479.6 2015-03-31
EP16305059 2016-01-22
EP16305059.4 2016-01-22
PCT/EP2016/056845 WO2016156346A1 (en) 2015-03-31 2016-03-30 Heterocyclic compounds and their use in preventing or treating bacterial infections

Publications (1)

Publication Number Publication Date
CA2980109A1 true CA2980109A1 (en) 2016-10-06

Family

ID=55642466

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2980109A Abandoned CA2980109A1 (en) 2015-03-31 2016-03-30 Heterocyclic compounds and their use in preventing or treating bacterial infections

Country Status (14)

Country Link
US (1) US10570131B2 (enExample)
EP (1) EP3277685B1 (enExample)
JP (1) JP2018510190A (enExample)
KR (1) KR20170131687A (enExample)
CN (1) CN107438610A (enExample)
AU (1) AU2016239207A1 (enExample)
BR (1) BR112017020826A2 (enExample)
CA (1) CA2980109A1 (enExample)
CL (1) CL2017002449A1 (enExample)
HK (1) HK1244791A1 (enExample)
MX (1) MX2017012539A (enExample)
RU (1) RU2715058C2 (enExample)
TW (1) TW201639853A (enExample)
WO (2) WO2016156344A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3300736B1 (en) * 2016-09-30 2021-05-05 Mutabilis Composition comprising antibiotic compound and an heterocyclic compound and their use in preventing or treating bacterial infections
EP3357924A1 (en) 2017-02-06 2018-08-08 Mutabilis Novel heterocyclic compounds and their use in preventing or treating bacterial infections
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
EP4272831A3 (en) 2018-08-09 2024-02-21 Antabio SAS Diazabicyclooctanones as inhibitors of serine beta-lactamases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5038509B2 (ja) * 2008-01-18 2012-10-03 メルク・シャープ・エンド・ドーム・コーポレイション β−ラクタマーゼ阻害剤
BR112013028813B1 (pt) 2011-08-27 2020-10-20 Wockhardt Limited derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e composições farmacêuticas que os compreendem
CN103649088B (zh) 2011-08-30 2016-05-11 沃克哈特有限公司 1, 6- 二氮杂双环[3, 2, 1]辛- 7- 酮衍生物及其在治疗细菌感染中的用途
AR090539A1 (es) 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
HUE046893T2 (hu) 2012-05-30 2020-04-28 Meiji Seika Pharma Co Ltd Új ß-laktamáz inhibitor és eljárás elõállítására
US9271446B2 (en) * 2012-06-28 2016-03-01 Forage Innovations B.V. Self-aligning apparatus and methods for gathering bales
ES2672100T3 (es) * 2012-08-25 2018-06-12 Wockhardt Limited Derivados de 1,6-diazabiciclo[3,2,1]octano-7-ona y su uso en el tratamiento de infecciones bacterianas
CN104994860A (zh) 2013-02-06 2015-10-21 阿斯利康(瑞典)有限公司 用于治疗医院性肺炎的组合疗法
WO2014141132A1 (en) * 2013-03-14 2014-09-18 Naeja Pharmaceutical Inc. NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS
MA41850A (fr) 2015-03-31 2018-02-06 Takeda Pharmaceuticals Co Nouvelles utilisations pharmaceutiques
EP3075734A1 (en) * 2015-03-31 2016-10-05 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
EP3075733A1 (en) 2015-03-31 2016-10-05 Mutabilis Novel heterocyclic compounds and their use in preventing or treating bacterial infections
GB201505585D0 (en) 2015-03-31 2015-05-13 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
RU2679652C1 (ru) 2015-03-31 2019-02-12 Лабораториос Баго С. А. Способ получения гранул с энтеросолюбильным покрытием, содержащих ингибитор протонного насоса, и фармацевтических композиций, состоящих из множества частиц и содержащих эти гранулы

Also Published As

Publication number Publication date
KR20170131687A (ko) 2017-11-29
TW201639853A (zh) 2016-11-16
CN107438610A (zh) 2017-12-05
EP3277685A1 (en) 2018-02-07
US20180086760A1 (en) 2018-03-29
JP2018510190A (ja) 2018-04-12
BR112017020826A2 (pt) 2018-07-03
WO2016156344A1 (en) 2016-10-06
CL2017002449A1 (es) 2018-04-20
RU2017133745A (ru) 2019-03-28
HK1244791A1 (zh) 2018-08-17
RU2017133745A3 (enExample) 2019-09-09
EP3277685B1 (en) 2021-01-13
AU2016239207A1 (en) 2017-10-12
MX2017012539A (es) 2018-09-28
RU2715058C2 (ru) 2020-02-25
US10570131B2 (en) 2020-02-25
WO2016156346A1 (en) 2016-10-06

Similar Documents

Publication Publication Date Title
EP3277277B1 (en) Heterocyclic compounds and their use in preventing or treating bacterial infections
EP3300736B1 (en) Composition comprising antibiotic compound and an heterocyclic compound and their use in preventing or treating bacterial infections
EP3277686B1 (en) Novel heterocyclic compounds and their use in preventing or treating bacterial infections
EP3394071B1 (en) Heterocyclic compounds and their use in preventing or treating bacterial infections
EP4086255A1 (en) Heterocyclic compounds and their use in preventing or treating bacterial infections
EP3277685B1 (en) Heterocyclic compounds and their use in preventing or treating bacterial infections
US11865118B2 (en) Heterocyclic compounds and their use in preventing or treating bacterial infections
EP3075734A1 (en) Heterocyclic compounds and their use in preventing or treating bacterial infections
EP3075381A1 (en) Heterocyclic compounds and their use in preventing or treating bacterial infections

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20220621